You are here

Can Cells Collected From Bone Marrow Repair Brain Damage in Babies With CHD?

PHILADELPHIA, PA (US), November 2019 — An upcoming clinical trial at Children's National Hospital will harness cardiopulmonary bypass as a delivery mechanism for a novel intervention designed to stimulate brain growth and repair in children who undergo cardiac surgery for congenital heart disease.

The NIH has awarded Children's National $2.5 million to test the hypothesis that mesenchymal stromal cells (MSCs), which have been shown to possess regenerative properties and the ability to modulate immune responses in a variety of diseases, collected from allogeneic bone marrow, may promote regeneration of damaged neuronal and glial cells in the early postnatal brain. If successful, the trial will determine the safety of the proposed treatment in humans and set the stage for a Phase 2 efficacy trial of what could potentially be the first treatment for brain damage in children with congenital heart disease.

The study is a single-center collaboration between three Children's National physician-researchers: Richard Jonas, M.D., Catherine Bollard, M.D. and Nobuyuki Ishibashi, M.D.

Learn more: